gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · UPBHealthcarePharmaceuticals

Upstream Bio, Inc. Common Stock (UPB)

$3.70+9.14%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$3.70▼ 85.22% in range
Nov 4, 2025Low $2.74 · High $32.60Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Upstream Bio closed at $3.70 on Nov 4, up 9.14%, 88.7% below its 52-week closing high. Volume of 1.2M shares was 0.95× its 20-day average (close to normal).

Split-adjusted performance: -19.4% over one month, -59.7% over six months, -85.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $773K, down 17.5% from a year earlier, with a net margin of -5136.1%.

Short interest was 4.5M shares at the Oct 15 settlement (13.2% of float, 3.7 days to cover).

Market cap$202.7M54.8M shares
Revenue · quarter$773.0K−17.5% YoY
Diluted EPS$-0.73—
P/E · TTM—P/S 64.2×
Net margin-5,136.1%Gross 100.0%
Dividend yieldNone
52-week range2.74 – 32.60−88.7% from high
Volume1.2M0.95× 20-day avg
Volatility · 60d84.2%Annualised
Short % of float13.2%3.7 days to cover
Net cash$261.3MCash $261.3M
Next earnings—Not scheduled
Split-adjusted performance
1W +24.2%1M −19.4%3M −46.1%6M −59.7%YTD −86.4%1Y −85.2%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum18
Revenue growth31
Net margin7
Value (low P/E)—
Size48

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short4.5M−0.8% vs prior
Days to cover3.7Settled Oct 15
% of float13.2%
Short vol. 10d19.0%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
UPBUpstream Bio$3.70+9.14%−59.7%−17.5%−5136.1%—$202.7M
NAGENiagen Bioscience$2.52+6.78%−49.3%−4.3%3.2%12.5$199.4MCompare
RNACCartesian Therapeutics$6.82+6.40%−18.2%−100.0%——$206.3MCompare
TRDAEntrada Therapeutics$5.06+7.20%−68.4%−53.9%−4762.0%—$197.0MCompare
AKBAAkebia Therapeutics$0.6947−4.28%−53.1%−21.4%−18.1%—$192.5MCompare
KROSKeros Therapeutics$10.830.00%−8.1%−100.0%——$214.7MCompare
ALXOALX Oncology Holdings$1.36+5.43%−34.9%———$188.1MCompare
EVMNEvommune$6.04+1.68%−74.7%———$219.2MCompare
ELDNEledon Pharmaceuticals$2.70+3.05%−28.9%———$219.4MCompare

News about Upstream Bio

All news →
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026GlobeNewswire Inc. · Sep 8, 2026▲ PositiveUpstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual MeetingGlobeNewswire Inc. · Mar 1, 2026▲ PositiveUpstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026GlobeNewswire Inc. · Feb 26, 2026▲ PositiveUpstream Bio to Participate in Upcoming March Investor ConferencesGlobeNewswire Inc. · Feb 25, 2026NeutralUpstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe AsthmaGlobeNewswire Inc. · Feb 10, 2026▲ Positive

Quick answers

What does Upstream Bio do?
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
What is UPB's market cap?
$202.65M, based on the Nov 4 close of $3.70.
Does Upstream Bio pay a dividend?
No regular cash dividend has been paid in the last year.
How much of UPB is sold short?
4.5M shares, 13.2% of float, as of Oct 15, 2026.
What sector is UPB in?
Healthcare, in the Pharmaceuticals industry.

About Upstream Bio

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).

HQ: Waltham, MA75 employeesListed Oct 11, 2024upstreambio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology